Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: www.outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

25_usa Jul. 31 at 12:18 AM

$OTLK looks like some good news coming out soon. Buy out also the option in the street.

1 · Reply

AnalystLLM Jul. 30 at 9:26 PM

$OTLK ???

0 · Reply

Bennyman369 Jul. 30 at 8:53 PM

$OTLK Volume increase day by day. Big boys accumulate before the 🌋. Let see if tomorrow we got over 2M in volume.

0 · Reply

Bennyman369 Jul. 30 at 8:46 PM

$OTLK $2.09 AH..... gap up tomorrow???

0 · Reply

GenerallyGentle Jul. 30 at 8:00 PM

$OTLK buying pressure is back

1 · Reply

CliffordCapital Jul. 30 at 7:59 PM

$OTLK bids rn

0 · Reply

adayxs Jul. 30 at 7:52 PM

$OTLK $OTLK Ok. I will bet. If it does what you say it will I will leave this board and never come back. If it does not you leave this board and never come back. @AnalystLLM Do we have a bet? $OTLK if mid August confirms the rumor 18k+ forms, the stock price is on the way to $30. 1500% increase in two weeks you might want to bet on it

1 · Reply

IniG Jul. 30 at 7:36 PM

$OTLK

0 · Reply

AnalystLLM Jul. 30 at 7:31 PM

$OTLK next 2 weeks i will repeat this message for those who concern

0 · Reply

IniG Jul. 30 at 7:27 PM

$OTLK

1 · Reply

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 8 days ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 4 weeks ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jun 18, 2025, 9:05 AM EDT - 6 weeks ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 7 weeks ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 2 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 2 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 2 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Apr 8, 2025, 8:45 AM EDT - 4 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025, 8:05 AM EST - 5 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 5 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 5 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 6 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 6 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 6 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 6 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 6 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 6 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 7 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 7 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 8 months ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 8 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 8 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 8 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 8 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 9 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 11 months ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 11 months ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 11 months ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 11 months ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Jul 30, 2024, 9:10 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 8, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:50 AM EDT - 1 year ago

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Jun 12, 2024, 10:00 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Jun 11, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Jun 6, 2024, 10:30 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

May 28, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

May 16, 2024, 2:35 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

May 15, 2024, 5:00 PM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

May 9, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

25_usa Jul. 31 at 12:18 AM

$OTLK looks like some good news coming out soon. Buy out also the option in the street.

1 · Reply

AnalystLLM Jul. 30 at 9:26 PM

$OTLK ???

0 · Reply

Bennyman369 Jul. 30 at 8:53 PM

$OTLK Volume increase day by day. Big boys accumulate before the 🌋. Let see if tomorrow we got over 2M in volume.

0 · Reply

Bennyman369 Jul. 30 at 8:46 PM

$OTLK $2.09 AH..... gap up tomorrow???

0 · Reply

GenerallyGentle Jul. 30 at 8:00 PM

$OTLK buying pressure is back

1 · Reply

CliffordCapital Jul. 30 at 7:59 PM

$OTLK bids rn

0 · Reply

adayxs Jul. 30 at 7:52 PM

1 · Reply

IniG Jul. 30 at 7:36 PM

$OTLK

0 · Reply

AnalystLLM Jul. 30 at 7:31 PM

$OTLK next 2 weeks i will repeat this message for those who concern

0 · Reply

IniG Jul. 30 at 7:27 PM

$OTLK

1 · Reply

AnalystLLM Jul. 30 at 7:19 PM

$OTLK no later on 8/17, your query to chatgpt with deep reasearch, like ”What LYTENAVA blueteq form number in July?” you will know the answer

0 · Reply

AnalystLLM Jul. 30 at 7:14 PM

$OTLK if mid August confirms the rumor 18k+ forms, the stock price is on the way to $30. 1500% increase in two weeks you might want to bet on it

0 · Reply

CliffordCapital Jul. 30 at 7:09 PM

$OTLK retested the ascending trendline today. 🤮🤮

0 · Reply

AnalystLLM Jul. 30 at 7:08 PM

$OTLK only 60 blueteq form in June for those want to push down the price. 150 vials is very close to truth. But in July 34 ICS are writing blueteq crazily.

0 · Reply

Britbox Jul. 30 at 7:07 PM

$OTLK don’t you dare touch $1.97 you bitch

1 · Reply

AnalystLLM Jul. 30 at 6:46 PM

$OTLK in 2.5 weeks the stock will up hugely you should buy now. Not fda approval or earning release. here it is ”In conclusion, the Blueteq dashboard is updated on a monthly schedule, so the form data for July (including all Lytenava entries) becomes available in the August update of the system”

0 · Reply

Lucky411 Jul. 30 at 6:42 PM

$OTLK

0 · Reply

Bennyman369 Jul. 30 at 5:40 PM

$OTLK 👀👇

0 · Reply

AnalystLLM Jul. 30 at 5:01 PM

$OTLK FDA approval means 60m dilution if there is no cash flow. What cfo said? no dilution plan is working on

0 · Reply

shawn45 Jul. 30 at 4:51 PM

$OTLK Looks like US FDA CMC site visit positive news could be coming in very soon, they way it's moving up slowly.. Something huge coming

1 · Reply

shawn45 Jul. 30 at 4:48 PM

$OTLK Shorts going to get burned soon, they try to buy cheaper and sell higher with Rinse and Repeat lol. Don't get smoked.

0 · Reply

AnalystLLM Jul. 30 at 4:47 PM

$OTLK 60% of post here the mission is to get stock back to 1.6 or no bonus by year end

0 · Reply

Market Cap	66.13M
Revenue (ttm)	0.00
Net Income (ttm)	-75.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.37

Volume	1,271,900
Avg Vol	880,100
Day's Range	N/A - N/A
Shares Out	33.57M
Stochastic %K	29%
Beta	0.25
Analysts	Strong Sell
Price Target	$9.00